Significant Momentum in Shift to Direct-to-Consumer Real Estate Focus;
Announced Share Repurchase Program Subsequent to Quarter End for up to $1 Million;
Announced Listing of Non-Core Asset in Chino Valley for $16 Million Subsequent to Year End
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million
Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product
REMINDER: Jaguar to host investor webcast Tuesday, May 14th at 8:30 a.m. Eastern regarding Q1 2024 financials and company updates; Click here to register for webcast
Read More$1.5 million in Adjusted EBITDA1, bringing the trailing 12 month Adjusted EBITDA1 to $5.8 million
Revenue of $10.7 million and Gross Margins improved by 1240 basis points year over year to 35%
Operating profit of $0.7 million with positive cash flow from operations for the quarter
Read More
Click here to register for May 14 investor webcast
Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024
Read More
